A Rs 15,000 monthly SIP for 5 years at 12 per cent annualised return can create an over Rs 2.07 crore corpus if one lets ...

Earnings statements are a staple of corporate communications, a twice-yearly (or sometimes quarterly) opportunity for a ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

Dr. Todd Ellerin says the compounded pharmacy drugs are regulated on the state level, but most do not possess FDA regulation like brand name drugs ...

Core & Main, Inc. (CNM) has strong growth prospects due to aging infrastructure, reshoring trends, and a recovering ...

Bill Malley, a Richland pharmacist who joined the U.S. military at 17 in 1943, posed with his dental hygienist at age 97 in ...

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Copart's relentless compounding potential and long-term growth prospects make it a valuable investment. Click to find out why ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...